Cao et al. have conducted trial test using lopinavir-ritonavir drugs for COVID-19 patients. They found that lopinavir-ritonavir treatment failed to significantly accelerate clinical improvement, reduce mortality, diminish throat viral RNA detectability in patients with serious COVID-19. In case of the severe COVID-19 adult patients, no benefit was observed with lopinavir-ritonavir treatment in comparison to the standard care group. Such study has found that lopinavir-ritonavir does not seem to be effective for COVID-19 patients and these combinations has produced more side effects.
Novel 2019 Coronavirus structure part 28
This entry was posted in Tak Berkategori. Bookmark the permalink.